Worse outcomes for immunosuppressed patients with cancer and COVID-19 treated...
A report published in JAMA Oncology suggests that cancer patients with baseline immunosuppression and COVID-19 experience worse outcomes and an increased incidence of cytokine storm when treated with...
View ArticleEMERALD: updated results on the impact of duration of prior CDK4/6i and FDA...
The U.S. Food and Drug Administration (FDA) has granted priority review for elacestrant, a selective estrogen receptor degrader (SERD), based on findings from the Phase III EMERALD trial...
View ArticleFDA approves combination therapy of tremelimumab, durvalumab, and...
The U.S. Food and Drug Administration (FDA) have approved tremelimumab in combination with durvalumab and platinum-based chemotherapy for metastatic non-small cell lung cancer (NSCLC) patients with no...
View ArticleTrastuzumab deruxtecan and the evolving HER2-low breast cancer landscape
VJOncology is excited to present the latest data and developments in the HER2-low breast cancer field, with comments from experts Paolo Tarantino, Mattia Rediti, and Rani Bansal. Practice-changing...
View ArticleFDA approves atezolizumab for unresectable or metastatic alveolar soft part...
On December 9th 2022, The US Food and Drug Administration (FDA) permitted the approval of atezolizumab for adult and pediatric patients 2 years of age and older with unresectable or metastatic...
View ArticleManaging urothelial carcinoma with targeted therapies
VJOncology is excited to present the latest data and developments in the bladder cancer field, with comments from Yohann Loriot, Jonathan Rosenberg, Petros Grivas and more. In the last four years, FDA...
View ArticleSPOTLIGHT: zolbetuximab plus chemotherapy prolongs PFS and OS in CLDN18.2+...
Primary results from the Phase III SPOTLIGHT (NCT03504397) trial demonstrated a significant survival benefit for patients with Claudin18.2 (CLDN18.2)-positive, HER2-negative, locally advanced...
View ArticleBWEL: a phone-based weight loss intervention in early-stage breast cancer
Initial data from the Phase III Breast Cancer Weight Loss Study (BWEL) (NCT02750826) has shown promising results for a telephone-based weight loss intervention program (WLI) in overweight and obese...
View ArticleSIENDO: long-term PFS findings of maintenance selinexor in TP53wt endometrial...
Endometrial cancer is the most common gynecological cancer, where approximately 417,000 cases and 100,000 deaths were reported worldwide in 2020.1 The incidence of endometrial cancer has additionally...
View ArticleEV-302/KEYNOTE-A39: combination enfortumab vedotin and pembrolizumab improves...
The Phase III EV-302/KEYNOTE-A39 (NCT04223856) trial demonstrated that the combination of enfortumab vedotin and pembrolizumab significantly improved overall survival (OS) and progression-free...
View ArticleFDA approves pembrolizumab in combination with chemoradiotherapy for cervical...
Cervical cancer remains a significant global health concern, particularly affecting women in resource-limited settings. According to the World Health Organization (WHO), cervical cancer is the fourth...
View ArticleFDA approves osimertinib with platinum-based chemotherapy in EGFR-mutated NSCLC
Lung cancer accounts for approximately one in ten cases of cancer, with non-small cell lung cancer (NSCLC) accounting for a substantial portion of cases.1 Targeted therapies have played a significant...
View ArticleNADINA trial establishes new standard in stage III melanoma treatment:...
The NADINA trial (NCT04949113) marks a significant milestone in melanoma treatment, representing the first Phase III trial to compare neoadjuvant immunotherapy with the standard adjuvant approach and...
View Article